On December 5, 2022, Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $165 million before deducting any offering related expenses. Karyopharm agreed to sell 31,791,908 shares of common stock at a price of $5.19 per share and to issue accompanying warrants to purchase 9,537,563 shares of common stock at an exercise price of $6.36 per share. The private placement was led by Avidity Partners with participation by existing and new investors including Adage Capital Partners LP, Armistice Capital, HealthCor Management LP, Heights Capital Management, Marshall Wace, Rubric Capital Management LP, SilverArc Capital and Surveyor Capital (a Citadel company).
The WilmerHale team advising Karyopharm included Jason Kropp, Craig Hilts, Rebecca Chang, Alex Bloom and Aric Jain.